TNFRSF17 and hematopoietic and lymphoid cell neoplasm: Until now, six (6) therapies have been approved by the FDA and EMA, targeting two TAAs, either CD19 or B-cell Maturation Antigen (BCMA), with the indication to treat hematological cancers.